Dossier assessment

Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-06
Last updated

Report documents

  1. Extract of dossier assessment

    Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 662 kB, EN, not accessible
  2. Dossier assessment

    Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 778 kB, DE, not accessible

Dossier assessment

Indication:

Moderate to severe atopic dermatitis in adults who are candidates for systemic therapy

Result of dossier assessment:

Indication of considerable added benefit

Additional information

Federal Joint Committee (G-BA)

07-07-2022 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A22-06
Commission
Commission awarded on 17.01.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Addendum

    Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06

    Project no.
    A22-60
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V

    Project no.
    A24-45
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form